Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11086MR)

This product GTTS-WQ11086MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11086MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1960MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ4528MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ13676MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ3481MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ814MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ6969MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ3705MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ1475MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW